Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.

ABSTRACT:

Background

The antidiabetic drug metformin has known anticancer effects related to its antioxidant activity; however, its clinical benefit for prostate cancer (PCa) has thus far been inconclusive. Here, we investigate whether the efficacy of metformin in PCa is related to the expression status of NKX3.1, a prostate-specific homeobox gene that functions in mitochondria to protect the prostate from aberrant oxidative stress.

Objective

To investigate the relationship of NKX3.1 expression and metformin efficacy in PCa.

Design, setting, and participants

Functional studies were performed in vivo and in vitro in genetically engineered mouse models and human LNCaP cells, and organotypic cultures having normal or reduced/absent levels of NKX3.1. Correlative studies were perfor

SUBMITTER: Papachristodoulou A 

PROVIDER: S-EPMC10902192 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature